Sophiris Bio - Reboundkanditat

http://www.nasdaq.com/de/symbol/sphs/real-time  

ihr das mit dem Produkt aus der Phase 3 könnte dort die Zulassung kommen nach dem fda Antrag.....
und wann wir dieser Antrag gestellt....  

http://seekingalpha.com/article/...io-far-topsalysins-fda-application  

schon länger auf Watch.

Wird 2017 in mein Depot wandern.  

denn hier ab ?  

http://www.finanzen.net/analyse/...Bio_Buy-Rodman__Renshaw_LLC_605570  

 

http://www.nasdaq.com/de/symbol/sphs/real-time

SPHS
$2.78
*  
0.3
12.1%  

http://www.reuters.com/article/...-provides-update-on-to-idUSASA09R1L  

https://seekingalpha.com/article/...ell-positioned-upcoming-catalysts  

dann lockt bei positiver News mit der aktuellen MK ein Tenbagger!

Drug Development/Clinical Research

BPH: The company successfully completed a Phase 3 clinical trial for the treatment of the symptoms of BPH. A single treatment with PRX302 (Topsalysin) demonstrated a statistically significant improvement in BPH symptoms over a 12-month period. The drug is designed to be as efficacious as pharmaceuticals, less invasive than surgical intervention, and without the sexual side effects seen with existing treatments.

The company already has a license agreement with Japan for commercialization of Topsalysin.

BPH is a $5 billion market with more than four million patients treated each year in the U.S. alone. The potential market for prostate cancer exceeds $1 billion.

The company is just one trial away from submitting an FDA application and can request the FDA to fast-track their application.  

schöner Schlussspurt!  

https://seekingalpha.com/article/...-digest-spotlighting-sophiris-bio  

Was für eine schöne Perle !  

 

http://www.nasdaq.com/de/symbol/sphs/real-time  

https://www.finanzen.net/analyse/Sophiris_Bio_Buy-Maxim_Group_636202  

Schöner move  

https://www.nasdaq.com/de/symbol/sphs/real-time  

https://seekingalpha.com/article/...os-upcoming-phase-2b-data-release  

 

https://www.nasdaq.com/de/symbol/sphs/real-time  

http://www.analystratings.com/articles/...phs-still-has-room-to-grow/